急性髓细胞性白血病核型与预后相关性的观察  

Clinical significance of karyotype in evaluating the prognosis of acute myeloid leukemia (non APL)

作　　者：张晓燕[1] 夏震[2] 李军民[2] 陈冰[2] 王晓敏[1] 沈志祥[2] 陈赛娟[2] 

机构地区：[1]新疆维吾尔自治区人民医院血液科,乌鲁木齐830001 [2]上海第二医科大学附属瑞金医院,上海血液学研究所,上海200025

出　　处：《诊断学理论与实践》2004年第6期438-441,共4页Journal of Diagnostics Concepts & Practice

摘　　要：目的:评价急性髓细胞性白血病中核型在预后评估中的意义。方法:回顾性分析102例初发急性髓细胞性白血病(非APL),按核型将其分为低危、中危、高危和未分类4组,评价核型在预后评估中的意义。结果:核型低危组、中危组和高危组的完全缓解率依次为76%、63%和55%,差异有显著性(P=0.0000294);低危组、中危组的总生存时间显著高于高危组(P值分别为0.0454和0.0421),3组的无病生存时间和2年生存率差异无显著性(P>0.05)。结论:急性髓细胞性白血病的细胞遗传学与预后具有相关性。Objective To evaluate the clinical significance of karyotype in prognosis of acute myeloid leukemia(non APL). Methods A hundred and two cases of de novo acute myeloid leukemia(non APL) were retrospective analyzed who were classified according to the karyotype into three cytogenetic risk groups (the favorable risk group, the intermediate-risk group and the high risk group) and the non-classfied group. Results There lied significant difference on the rates of complete remission in the favorable risk group(76%), the intermediate-risk group(63%) and the high risk group(55%) (P=0.0000294). The overall survival time in the favorable risk group and the intermediate-risk group was significantly longer than that in the high risk group(P=0.0454 and 0.0421 respectively). There was no difference on the disease-free survival (DFS) and the rate of 2-year survival among these three groups (P=0.6254 and 0.623). Conclusions The karyotype has a correlation with the prognosis of acute myeloid leukemia(non APL).

关 键 词：急性髓细胞性白血病 核型 预后 遗传学 

分 类 号：R733.71[医药卫生—肿瘤]